company background image
CDXC

ChromaDex NasdaqCM:CDXC Stock Report

Last Price

US$1.92

Market Cap

US$131.6m

7D

17.1%

1Y

-79.0%

Updated

26 Jun, 2022

Data

Company Financials +
CDXC fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

CDXC Stock Overview

ChromaDex Corporation operates as a bioscience company focusing on healthy aging.

ChromaDex Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for ChromaDex
Historical stock prices
Current Share PriceUS$1.92
52 Week HighUS$10.78
52 Week LowUS$1.51
Beta1.78
1 Month Change9.71%
3 Month Change-18.99%
1 Year Change-79.04%
3 Year Change-58.71%
5 Year Change-49.74%
Change since IPO-82.93%

Recent News & Updates

Shareholder Returns

CDXCUS Life SciencesUS Market
7D17.1%8.4%6.6%
1Y-79.0%-15.9%-18.4%

Return vs Industry: CDXC underperformed the US Life Sciences industry which returned -15.9% over the past year.

Return vs Market: CDXC underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is CDXC's price volatile compared to industry and market?
CDXC volatility
CDXC Average Weekly Movement13.7%
Life Sciences Industry Average Movement11.4%
Market Average Movement8.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: CDXC is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: CDXC's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a115Rob Friedhttps://www.chromadex.com

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.

ChromaDex Fundamentals Summary

How do ChromaDex's earnings and revenue compare to its market cap?
CDXC fundamental statistics
Market CapUS$131.55m
Earnings (TTM)-US$27.49m
Revenue (TTM)US$70.03m

1.9x

P/S Ratio

-4.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CDXC income statement (TTM)
RevenueUS$70.03m
Cost of RevenueUS$27.24m
Gross ProfitUS$42.79m
Other ExpensesUS$70.28m
Earnings-US$27.49m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.40
Gross Margin61.10%
Net Profit Margin-39.25%
Debt/Equity Ratio0%

How did CDXC perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is CDXC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CDXC?

Other financial metrics that can be useful for relative valuation.

CDXC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.6x
Enterprise Value/EBITDA-4.4x
PEG Ration/a

Price to Sales Ratio vs Peers

How does CDXC's PS Ratio compare to its peers?

CDXC PS Ratio vs Peers
The above table shows the PS ratio for CDXC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average8.9x

Price-To-Sales vs Peers: CDXC is good value based on its Price-To-Sales Ratio (1.9x) compared to the peer average (8.9x).


Price to Earnings Ratio vs Industry

How does CDXC's PE Ratio compare vs other companies in the U.S. Life Sciences Industry?

Price-To-Sales vs Industry: CDXC is good value based on its Price-To-Sales Ratio (1.9x) compared to the US Life Sciences industry average (5.2x)


Price to Sales Ratio vs Fair Ratio

What is CDXC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CDXC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.9x
Fair PS Ratio4.6x

Price-To-Sales vs Fair Ratio: CDXC is good value based on its Price-To-Sales Ratio (1.9x) compared to the estimated Fair Price-To-Sales Ratio (4.6x).


Share Price vs Fair Value

What is the Fair Price of CDXC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CDXC ($1.92) is trading below our estimate of fair value ($18.32)

Significantly Below Fair Value: CDXC is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CDXC's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is ChromaDex forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


68.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CDXC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: CDXC is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CDXC is expected to become profitable in the next 3 years.

Revenue vs Market: CDXC's revenue (22.5% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: CDXC's revenue (22.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CDXC's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has ChromaDex performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-9.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CDXC is currently unprofitable.

Growing Profit Margin: CDXC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CDXC is unprofitable, and losses have increased over the past 5 years at a rate of 9.7% per year.

Accelerating Growth: Unable to compare CDXC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CDXC is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (21%).


Return on Equity

High ROE: CDXC has a negative Return on Equity (-106.22%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is ChromaDex's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: CDXC's short term assets ($44.5M) exceed its short term liabilities ($18.7M).

Long Term Liabilities: CDXC's short term assets ($44.5M) exceed its long term liabilities ($8.4M).


Debt to Equity History and Analysis

Debt Level: CDXC is debt free.

Reducing Debt: CDXC had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CDXC has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CDXC has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 18.9% each year.


Discover healthy companies

Dividend

What is ChromaDex current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CDXC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CDXC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CDXC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CDXC's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CDXC has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Rob Fried (61 yo)

4yrs

Tenure

US$1,103,160

Compensation

Mr. Robert N. Fried, also known as Rob, has been the Chief Executive Officer of ChromaDex Corp. since June 22, 2018 and its a Director since July 2015. Mr. Fried was the Chief Operating Officer of ChromaDe...


CEO Compensation Analysis

Compensation vs Market: Rob's total compensation ($USD1.10M) is above average for companies of similar size in the US market ($USD752.25K).

Compensation vs Earnings: Rob's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CDXC's management team is considered experienced (3.8 years average tenure).


Board Members

Experienced Board: CDXC's board of directors are considered experienced (5.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CDXC insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

ChromaDex Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: ChromaDex Corporation
  • Ticker: CDXC
  • Exchange: NasdaqCM
  • Founded: NaN
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$131.554m
  • Shares outstanding: 68.52m
  • Website: https://www.chromadex.com

Number of Employees


Location

  • ChromaDex Corporation
  • 10900 Wilshire Boulevard
  • Suite 600
  • Los Angeles
  • California
  • 90024
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/26 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.